General, Pancreatic cancer, Colorectal cancer, Non-small cell lung cancer (NSCLC)
Second line + Treatment (Metastatic Disease)
KRAS G12D
Trial J5J-OX-JZZA is a Phase 1a/1b study evaluating the compound LY3962673 in participants with advanced solid tumors harboring a KRAS G12D mutation. The primary objective is to assess the safety, tolerability, and antitumor activity of LY3962673 administered as monotherapy or in combination with other cytotoxic agents. The study enrolls adult patients with advanced or metastatic solid tumor types. Molecular eligibility regarding the KRAS G12D status is confirmed during the screening period. Participants are assigned to receive the study drug either as a single agent or in combination regimens. Key endpoints include dose-limiting toxicities, objective response rates, and the pharmacokinetic profile of the intervention.
This clinical study evaluates a new drug called LY3962673 for patients with advanced solid tumors that carry a specific genetic change known as a KRAS G12D mutation. The main goal of the research is to determine the safety and tolerability of the drug and to see how effectively it acts against the cancer. Participants receive the medication either as a single treatment or combined with standard chemotherapy. The study is open to adults whose cancer has reached an advanced stage. Before starting, a test is performed to confirm the presence of the specific mutation in the tumor. The study is planned to last approximately five years.
